Karyopharm Therapeutics is pursuing financing or strategic alternatives while cutting about 20% of staff.
- Talks with potential investors have not resulted in a deal
- Strategic options include M&A, restructurings, debt refinancing
- Board continues evaluating potential transactions
- Related expenses from job cuts seen as immaterial
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2025 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.